Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Amortization of Deferred Charges: 2015-2023

Historic Amortization of Deferred Charges for Cartesian Therapeutics (RNAC) over the last 8 years, with Sep 2023 value amounting to -$78,000.

  • Cartesian Therapeutics' Amortization of Deferred Charges fell 139.39% to -$78,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $631,000, marking a year-over-year decrease of 36.20%. This contributed to the annual value of $455,000 for FY2023, which is 52.26% down from last year.
  • Cartesian Therapeutics' Amortization of Deferred Charges amounted to -$78,000 in Q3 2023, which was down 157.78% from $135,000 recorded in Q2 2023.
  • Cartesian Therapeutics' 5-year Amortization of Deferred Charges high stood at $398,000 for Q1 2023, and its period low was -$78,000 during Q3 2023.
  • Over the past 3 years, Cartesian Therapeutics' median Amortization of Deferred Charges value was $206,000 (recorded in 2021), while the average stood at $220,000.
  • As far as peak fluctuations go, Cartesian Therapeutics' Amortization of Deferred Charges spiked by 314.00% in 2021, and later slumped by 139.39% in 2023.
  • Over the past 5 years, Cartesian Therapeutics' Amortization of Deferred Charges (Quarterly) stood at $64,000 in 2019, then skyrocketed by 234.38% to $214,000 in 2020, then dropped by 0.93% to $212,000 in 2021, then decreased by 16.98% to $176,000 in 2022, then tumbled by 139.39% to -$78,000 in 2023.
  • Its Amortization of Deferred Charges was -$78,000 in Q3 2023, compared to $135,000 in Q2 2023 and $398,000 in Q1 2023.